-
Jun 2012
Zinc transporter-8 autoantibodies improve prediction of type 1 diabetes in relatives positive for the standard biochemical autoantibodies.
Diabetes CareYu L, Boulware DC, Beam CA, Hutton JC, Wenzlau JM, Greenbaum CJ, Bingley PJ, Krischer JP, Sosenko JM, Skyler JS, Eisenbarth GS, Mahon JL, Type 1 Diabetes TrialNet Study Group. -
Jun 2012
Through the fog: recent clinical trials to preserve β-cell function in type 1 diabetes.
DiabetesGreenbaum CJ, Schatz DA, Haller MJ, Sanda S -
May 2012
Perspective: Rethink the immune connection.
NatureGreenbaum CJ -
Mar 2012
Dead or alive?
Diabetes CareGreenbaum CJ -
Jan 2012
Altered B cell homeostasis is associated with type I diabetes and carriers of the PTPN22 allelic variant.
J ImmunolHabib T, Funk A, Rieck M, Brahmandam A, Dai X, Panigrahi AK, Luning Prak ET, Meyer-Bahlburg A, Sanda S, Greenbaum CJ, Rawlings DJ, Buckner JH -
Dec 2011
Effect of rituximab on human in vivo antibody immune responses.
J Allergy Clin ImmunolPescovitz MD, Torgerson TR, Ochs HD, Ocheltree E, McGee P, Krause-Steinrauf H, Lachin JM, Canniff J, Greenbaum CJ, Herold KC, Skyler JS, Weinberg A, Type 1 Diabetes TrialNet Study Group. -
Dec 2011
Making progress: preserving beta cells in type 1 diabetes.
Ann N Y Acad SciGallagher MP, Goland RS, Greenbaum CJ -
Sep 2011
Metabolic tests to determine risk for type 1 diabetes in clinical trials.
Diabetes Metab Res RevGreenbaum CJ, Buckingham B, Chase HP, Krischer J, Diabetes Prevention Trial, Type 1 Diabetes (DPT-1) Study Group. -
Aug 2011
Validation of the Diabetes Prevention Trial-Type 1 Risk Score in the TrialNet Natural History Study.
Diabetes CareSosenko JM, Skyler JS, Mahon J, Krischer JP, Beam CA, Boulware DC, Greenbaum CJ, Rafkin LE, Cowie C, Cuthbertson D, Palmer JP, Type 1 Diabetes TrialNet and Diabetes Prevention Trial-Type 1 Study Groups. -
Jul 2011
Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial.
LancetOrban T, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Marks JB, Monzavi R, Moran A, Raskin P, Rodriguez H, Russell WE, Schatz D, Wherrett D, Wilson DM, Krischer JP, Skyler JS, Type 1 Diabetes TrialNet Abatacept Study Group. -
Jul 2011
Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial.
LancetWherrett DK, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Herold KC, Marks JB, Monzavi R, Moran A, Orban T, Palmer JP, Raskin P, Rodriguez H, Schatz D, Wilson DM, Krischer JP, Skyler JS, Type 1 Diabetes TrialNet GAD Study Group. -
Jun 2011
Comment on: Atkinson. It's time to consider changing the rules: the rationale for rethinking control groups in clinical trials aimed at reversing type 1 diabetes. Diabetes 2011;60:361-363.
DiabetesSanda S, Greenbaum CJ -
May 2011
Parenteral insulin suppresses T cell proliferation to islet antigens.
Pediatr DiabetesGreenbaum CJ, McCulloch-Olson M, Chiu HK, Palmer JP, Brooks-Worrell B -
Apr 2011
Interaction of onset and duration of diabetes on the percent of GAD and IA-2 antibody-positive subjects in the type 1 diabetes genetics consortium database.
Diabetes CareTridgell DM, Spiekerman C, Wang RS, Greenbaum CJ -
Mar 2011
A comparison of the baseline metabolic profiles between Diabetes Prevention Trial-Type 1 and TrialNet Natural History Study participants.
Pediatr DiabetesSosenko JM, Mahon J, Rafkin L, Lachin JM, Krause-Steinrauf H, Krischer JP, Cuthbertson D, Palmer JP, Thompson C, Greenbaum CJ, Skyler JS, Diabetes Prevention Trial-Type 1 and TrialNet Study Groups.
